These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35510486)

  • 1. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
    Mascarenhas J; Harrison CN; Kiladjian JJ; Komrokji RS; Koschmieder S; Vannucchi AM; Berry T; Redding D; Sherman L; Dougherty S; Peng L; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Verstovsek S
    Future Oncol; 2022 Jul; 18(22):2393-2402. PubMed ID: 35510486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
    Kuykendall AT; Sun L; Mascarenhas J; Kiladjian JJ; Vannucchi AM; Wang J; Xia Q; Zhu E; Feller F; Rizo A; Bussolari J; Wan Y; Komrokji R
    Ann Hematol; 2022 Jan; 101(1):139-146. PubMed ID: 34622316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
    Mascarenhas J; Komrokji RS; Palandri F; Martino B; Niederwieser D; Reiter A; Scott BL; Baer MR; Hoffman R; Odenike O; Vannucchi AM; Bussolari J; Zhu E; Rose E; Sherman L; Dougherty S; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Kiladjian JJ
    J Clin Oncol; 2021 Sep; 39(26):2881-2892. PubMed ID: 34138638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Clinical Investigations in Myelofibrosis.
    Venugopal S; Mascarenhas J
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):353-373. PubMed ID: 33641874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
    Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
    N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
    Bose P; Mesa RA
    Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
    Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental Therapeutics in Myeloproliferative Neoplasms.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S43-S52. PubMed ID: 28760302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.